SAN DIEGO, Jan. 25 /PRNewswire-FirstCall/ -- Sequenom, Inc. today announced that a Company-sponsored poster that confirms a key developmental milestone for future non-invasive prenatal diagnostic tests will be presented at the 27th Annual Meeting of the Society of Maternal-Fetal Medicine, to be held February 5 to 10, 2007, in San Francisco. The poster will be presented on February 9, 2007 at 3:30 p.m. Pacific Time.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO )
"We are pleased that our poster was selected for presentation at this highly respected and well attended meeting," said Harry Stylli, Ph.D., President and Chief Executive Officer of Sequenom. "This meeting provides us with an opportunity to introduce our Fetal Nucleic Acid Technology to key members of the medical community as we prepare to introduce our first non-invasive prenatal diagnostic test (home brew) for Rhesus D in the first half of 2007."
About Sequenom
Sequenom is committed to providing the best genetic analysis products that translate genomic science into superior solutions for biomedical research, agricultural applications, molecular medicine, and non-invasive prenatal testing. The Company's proprietary MassARRAY(R) system is a high-performance DNA analysis platform that efficiently and precisely measures the amount of genetic target material and variations therein. The system is able to deliver reliable and specific data from complex biological samples and from genetic target material that is only available in trace amounts. The Company has exclusively licensed intellectual property rights for the development and commercialization of non-invasive prenatal genetic tests for use with the MassARRAY system and other platforms.
Sequenom(R), MassARRAY(R), and iPLEX(TM) are trademarks of SEQUENOM, Inc.
Except for the historical information contained in this press release, the matters set forth herein, including statements regarding the Company's plans to present its poster at the Society of Maternal-Fetal Medicine Annual Meeting, future non-invasive prenatal diagnostic tests, the Company's expected introduction of its first non-invasive prenatal diagnostic test (home brew) for Rhesus D in the first half of 2007, and Sequenom's plans to develop and commercialize prenatal genetic tests for use with its systems or other platforms are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with reliance upon the efforts of collaborative partners, new technology development, product development and commercialization, government regulation, obtaining or maintaining regulatory approvals, the Company's technologies, and other risks detailed from time to time in the Company's SEC filings, including the Company's Annual Report on Form 10-K for the year ended December 31, 2005, the Company's most recently filed quarterly report on Form 10-Q, and other documents subsequently filed with or furnished to the U.S. Securities and Exchange Commission (SEC). These forward-looking statements are based on current information that is likely to change. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comSequenom, Inc.CONTACT: Susan Gammon, Ph.D., Director of Marketing, Molecular Diagnosticsof Sequenom, Inc., +1-858-202-9192; or Media, David Schemelia of HealthSTARPublic Relations, +1-646-722-8819, dschemelia@healthstarpr.com, forSequenom, Inc.; or Investor Relations, Zachary Bryant, zbryant@lhai.com, orJody Cain, jcain@lhai.com, both of Lippert/Heilshorn & Associates,+1-310-691- 7100, for Sequenom, Inc.
